• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

Mr. Free At 33

Dividends • Stocks • Investing

  • My Story
  • Coaching
  • Portfolio
  • Getting Started
  • Media Mentions
  • Contact

Undervalued Dividend Growth Stock Of The Week

April 30, 2017 by Jason Fieber 14 Comments

I uncover a high-quality dividend growth stock that appears to be undervalued each week for Daily Trade Alert, which is a site that focuses on dividend growth investing, stocks, and unique investment opportunities. I’ve been writing for them for years now, and they’re just great over there. Each week, I publish an excerpt of my work, when it’s fresh off the press. That way, you readers are given the opportunity to check it out. The content is totally free. I hope you enjoy!

It’s amazing how straightforward building real and lasting wealth and passive income can be.

Society had me tricked for so long, having me believe that it was some kind of fairy tale reserved for the lucky and/or powerful few that kept all the secrets to themselves.

But there’s no secret at all.

However, there’s some hard work involved, which is quite possibly enough to turn away a lot of people.

Nonetheless, if you’re willing to work hard, live below your means, and invest your capital intelligently, financial freedom can be yours.

Keep reading…

Image courtesy of: Stuart Miles at FreeDigitalPhotos.net.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)

Filed Under: Dividend Growth Investing

About Jason Fieber

Jason Fieber became financially free at 33 years old by using dividend growth investing to his advantage. Jason has authored two best-selling books: The Dividend Mantra Way and 5 Steps To Retire In 5 Years (also available in paperback).

 

Jason recommends Personal Capital for portfolio management, Mint for budgeting, Schwab for the brokerage account, and Morningstar, Daily Trade Alert, and Motley Fool for stock ideas. This blog is hosted by Bluehost. If you'd like to start your own blog, Jason offers free coaching when you use our Bluehost affiliate link.

 

Jason's writing and/or story has been featured across international media like USA Today, Business Insider, and CNBC.

« Three Ways To Limit Food Costs: Helping The Wallet And The Waistline
It’s Not About The Money: Being A Homebody »

Reader Interactions

Comments

  1. Tall Investing says

    April 30, 2017 at 5:17 pm

    Thanks Jason, continue to like these posts.

    Like you I own 40 shares of Abbvie. They have proven to be a steady dividend payer with good growth at an already above average level.

    Cheers,
    Tall Investing

    Reply
    • Jason Fieber says

      April 30, 2017 at 5:30 pm

      TI,

      Tough to dislike AbbVie. You’re getting above-average yield and growth at a below-average valuation. I think the latter exists because of the reliance on one product, which is a significant risk. Nonetheless, it’s a high-quality business that is doing incredibly well. Moreover, one should diversify appropriately so as to mitigate that risk.

      Thanks for stopping by!

      Best regards.

      Reply
  2. DivHut says

    April 30, 2017 at 5:32 pm

    Agreed. Tough to dislike ABBV. It’s one of my larger positions and has been with me since the ABT spin off. It’s a keeper for the foreseeable future.

    Reply
    • Jason Fieber says

      April 30, 2017 at 7:09 pm

      Keith,

      A keeper, indeed. Have no plans to offload this one. 🙂

      Cheers.

      Reply
  3. FiscalVoyage says

    April 30, 2017 at 6:28 pm

    I like ABBV. I am full position in my portfolio with this company. Thanks for the review of this company.

    Reply
    • Jason Fieber says

      April 30, 2017 at 7:09 pm

      FV,

      Glad to be a fellow shareholder. We should continue to do well over the long haul.

      Best wishes!

      Reply
  4. Buy, Hold Long says

    May 1, 2017 at 4:14 am

    ABBV is one of the first international stocks I have ever considered. Great post.

    Reply
    • Jason Fieber says

      May 1, 2017 at 11:45 am

      BHL,

      Thanks. Glad you enjoyed it!

      Cheers.

      Reply
  5. Michael says

    May 1, 2017 at 9:07 am

    Hi Jason
    A great article on ABBV Jason. No doubt a great company and dividend payer. I agree with what you wrote on ABBV, and ABBV has done a great job in creating share holders value. I am long ABBV and have 193 shares and if it pulls back some would love to add to my position.
    Cheers

    Reply
    • Jason Fieber says

      May 1, 2017 at 3:39 pm

      Michael,

      Happy to be a fellow shareholder. It’s a great company. The reliance on Humira is a key risk, but the valuation seems to be pricing much of that in. Meanwhile, you’re getting paid a healthy dividend while they diversify the business. Tough to not like that.

      Thanks for dropping by!

      Best wishes.

      Reply
  6. Duncan's Dividends says

    May 1, 2017 at 3:35 pm

    Love this pick and it’s definitely on my radar as well. I just bought 100 shares each of KO and XOM and added 86 to my VIG position so I’m waiting to stock back up to pick up a few shares myself. Thanks for the great write up.

    Reply
    • Jason Fieber says

      May 1, 2017 at 3:38 pm

      DD,

      Hey, I’m happy to share these ideas. S&P Capital IQ looks a little aggressive with their FV, but the stock still appears to be one of the more compelling dividend growth stocks available when considering the valuation, growth, and yield. 🙂

      Best regards!

      Reply
  7. Mike H says

    May 2, 2017 at 1:17 am

    I agree ABBV is a good company. I picked up 100 shares three months back when it was at $60.60, and remain a happy shareholder. Looking for some diversification of the product line.

    -Mike

    Reply
    • Jason Fieber says

      May 2, 2017 at 1:25 am

      Mike,

      Agreed. They need to continue to build out, but I think the valuation, in part, reflects that need. Nonetheless, the growth and yield combine to make a pretty compelling case. 🙂

      Cheers!

      Reply

Join the discussion. Let's have a dialogue. Just please make sure comments are respectful and relevant. Cancel reply

Primary Sidebar

About Me

About Me

Hi. I'm Jason Fieber. I achieved financial independence and retired in my early 30s by using dividend growth investing to my advantage. I cover stock analyses, market news, dividend updates, and the dividend growth investing strategy.

Recommended

My Best-Selling Books

My Best-Selling Books

Let’s Stay In Touch

  • Facebook
  • Twitter

As Seen In

As Seen In

Most Popular

  • Two Big Reasons Behind My Decision To Move Overseas And Become A Dividend Expat 119 comments
  • Financial Freedom Should Be Just One Chapter Of An Otherwise Fantastic Book 110 comments
  • My Recent Experience With Visiting A Hospital In Chiang Mai, Thailand 106 comments
  • Why I Moved Most Of My Assets From Scottrade to Charles Schwab (And Why You May Want To Do The Same) 96 comments
  • It’s Not About The Money: Rent Versus Buy 91 comments

Search

Archives

Categories

Footer

Disclaimer

I’m not a licensed professional of any kind. I’m not a financial advisor, tax professional, or doctor. This site should be viewed for entertainment purposes only. Before you invest any of your money, exercise, or undergo any financial, business, or personal changes at all, please consult an appropriate professional. Unless your investments are FDIC insured, they may decline in value. Any stock transactions and/or analyses I publish should not be considered to be investment recommendations. I am not liable for any losses or suffering experienced by any party.

Privacy Policy

This site does not attempt to collect any personal information whatsoever other than that which is freely shared publicly (through comments), or that which is collected automatically via servers and Google Analytics. I do not sell or voluntarily disclose anyone’s personal information to anyone.

Disclosure

This site is largely supported by way of advertisements. As such, third-party ads may be served up at any time, and I may be paid on your clicking of these ads or your giving of information to third-party representatives. I offer no guarantees as to the accuracy of these ads. These ads may not necessarily reflect or represent my opinions or viewpoints. In addition, I may also have affiliate partnerships with companies whereby I earn a commission if products and/or services are purchased after you click on a link from this site. I only set up affiliate relationships with companies who offer products and/or services that I personally believe in and/or personally use. If I don’t believe in a product and/or service, I don’t endorse it.

Copyright © 2016-2020 Mr. Free At 33. All rights reserved.
sponsored

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Mr. Free At 33
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping us to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.